Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of 7.750-8.250 for the period, compared to the consensus earnings per share estimate of 8.010. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion.

Wall Street Analyst Weigh In

Several brokerages recently commented on HALO. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Benchmark upped their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Weiss Ratings cut Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Finally, HC Wainwright upped their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $80.67.

Halozyme Therapeutics Stock Up 6.8%

Shares of Halozyme Therapeutics stock opened at $70.93 on Wednesday. The stock has a market capitalization of $8.40 billion, a P/E ratio of 25.51, a PEG ratio of 0.27 and a beta of 0.89. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The stock has a 50 day moving average price of $65.70 and a two-hundred day moving average price of $68.60. Halozyme Therapeutics has a 12-month low of $47.50 and a 12-month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 175.89% and a net margin of 23.13%.The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same period in the previous year, the company earned $1.11 earnings per share. The company’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts expect that Halozyme Therapeutics will post 7.68 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the transaction, the director directly owned 38,498 shares in the company, valued at $2,443,853.04. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total value of $1,284,800.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $49,322,187.20. This trade represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 90,482 shares of company stock worth $6,073,942 over the last three months. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Halozyme beat Q1 expectations, with revenue rising 42% year over year to about $377 million and EPS of $1.60 topping estimates, reinforcing the company’s strong commercial and royalty growth. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Positive Sentiment: The company authorized a new $1 billion share repurchase program and said it expects to buy back at least $400 million of stock in 2026, which signals confidence in cash generation and can support the share price. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Positive Sentiment: Halozyme reiterated 2026 guidance calling for $1.71 billion to $1.81 billion in total revenue and $7.75 to $8.25 in non-GAAP EPS, suggesting management remains confident about full-year performance. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Positive Sentiment: The new global collaboration and license agreement with GSK expands ENHANZE’s potential royalty runway and adds to Halozyme’s partnership-driven growth story. Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK
• Neutral Sentiment: Morgan Stanley trimmed its price target on HALO to $93 from $96, but still kept an overweight rating, indicating continued optimism despite the modest target cut. Benzinga

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HALO. Abel Hall LLC lifted its holdings in Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 129 shares during the last quarter. StoneX Group Inc. raised its holdings in Halozyme Therapeutics by 3.8% in the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 132 shares in the last quarter. Coldstream Capital Management Inc. raised its holdings in Halozyme Therapeutics by 1.9% in the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock valued at $654,000 after acquiring an additional 165 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares in the last quarter. Finally, Private Advisor Group LLC raised its holdings in Halozyme Therapeutics by 0.8% in the 3rd quarter. Private Advisor Group LLC now owns 23,623 shares of the biopharmaceutical company’s stock valued at $1,733,000 after acquiring an additional 184 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.